Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching.

Yoshihiro Furuichi Hirohito Takeuchi Yuu Yoshimasu Yoshitaka Kasai Masakazu Abe Takao Itoi

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2020)

Lusutrombopag was more effective in chronic liver disease patients than platelet transfusion. The proportion of responders, effect duration, and non-incidence rate of adverse events were higher in the lusutrombopag group.

Keyphrases

end stage renal disease
cardiac surgery
newly diagnosed
ejection fraction
chronic kidney disease
risk factors
prognostic factors
peritoneal dialysis
sickle cell disease
acute kidney injury
drug induced
patient reported